#TORRENT PHARMA DERMA PRODUCTS TORRENT#
Torrent Pharmaceuticals operates in more than 40 countries with over 2000 product registrations globally. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd. “A fast approval process and successful US FDA resolution for the Srikakulam plant could drive a substantial stock re-rating,” noted CLSA. Torrent Pharma enjoys dominance in the niche therapeutic areas like, cardiovascular and central nervous system, gastro-intestinal, pain management and oral anti-diabetic segments. Is the flagship company of the Torrent Group.Based in the Indian city of Ahmedabad.It was promoted by U. Moreover, favourable outcomes on litigation related to Nuvaring and Suboxone sublingual film will provide further visibility on US sales growth in the next two years, added CLSA. Maintaining ‘buy’ and target price of Rs 3,620, CLSA said a meaningful revival in drug approvals in the second half of the current financial year will be a key factor for recovery in US business growth. The brokerage has raised target price on Torrent Pharma to Rs 1,810 from Rs 1,640 while retaining a ‘buy’ rating. This provides strong earnings growth visibility for the company,” said CLSA in the note. “We expect India and Brazil to contribute 63% of the incremental growth over this period. The brokerage forecasts Lupin to post mid-teen earnings growth despite a high concentration on some products.Įstimating the company’s earnings to grow at 24% on a compounded basis between FY17 and FY19, CLSA said the company’s strong positoning in branded generic markets such as India and Brazil are likely to help to sustain premium valuations. “It's differentiated pipeline in respiratory and biosimilars is making gradual progress, which will support the longer-term outlook,” said CLSA. The brokerage has upgraded shares of Lupin to ‘buy’ from ‘outperform’ and raised target price by 6.7% to Rs 1,760 citing strong drug approval cycle in the US.
0 kommentar(er)
